1584 related articles for article (PubMed ID: 9973838)
1. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
2. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
3. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
4. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
5. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
Heng BC; Cao T
Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
[TBL] [Abstract][Full Text] [Related]
6. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
7. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
8. Designer genes: recombinant antibody fragments for biological imaging.
Wu AM; Yazaki PJ
Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
[TBL] [Abstract][Full Text] [Related]
9. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen.
Zhang JL; Gou JJ; Zhang ZY; Jing YX; Zhang L; Guo R; Yan P; Cheng NL; Niu B; Xie J
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):237-41. PubMed ID: 16698583
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
[TBL] [Abstract][Full Text] [Related]
11. Medical applications of single-chain antibodies.
Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H
Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
14. Single-chain antibodies in pancreatic cancer.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Batra SK
Ann N Y Acad Sci; 1999 Jun; 880():263-80. PubMed ID: 10415872
[TBL] [Abstract][Full Text] [Related]
15. Anti-estradiol-17beta single-chain Fv fragments: Generation, characterization, gene randomization, and optimized phage display.
Kobayashi N; Kato Y; Oyama H; Taga S; Niwa T; Sun P; Ohtoyo M; Goto J
Steroids; 2008 Dec; 73(14):1485-99. PubMed ID: 18824188
[TBL] [Abstract][Full Text] [Related]
16. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
17. In vivo targeting of malignant melanoma by 125Iodine- and 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen.
Kang N; Hamilton S; Odili J; Wilson G; Kupsch J
Clin Cancer Res; 2000 Dec; 6(12):4921-31. PubMed ID: 11156253
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen.
Bejcek BE; Wang D; Berven E; Pennell CA; Peiper SC; Poppema S; Uckun FM; Kersey JH
Cancer Res; 1995 Jun; 55(11):2346-51. PubMed ID: 7538901
[TBL] [Abstract][Full Text] [Related]
19. Effects of genetic engineering on the pharmacokinetics of antibodies.
Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK
Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508
[TBL] [Abstract][Full Text] [Related]
20. Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg.
Yang X; Hu W; Li F; Xia H; Zhang Z
Protein Expr Purif; 2005 Jun; 41(2):341-8. PubMed ID: 15866720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
